2013-09-30 13:08:31 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Antares Pharma Inc (ATRS) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Antares Pharma Inc (ATRS). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Antares Pharma Inc investor.
Report Summary: Antares Pharma Inc is a below average quality company with a neutral outlook. Antares Pharma Inc has strong business growth and is run by inefficient management. The trend in Antares Pharma Inc fair value exchange rate against its closest rated-competitor, Cardiovascular Systems Inc, has been depreciating over the past 2 weeks. When compared to its closest competitor, Antares Pharma Inc shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its
three components - business, management and price, performing an in-depth analysis of Antares Pharma Inc for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.